Symcel’s new engineer is increasing production and R&D capacity
Our Production and Application Engineer, Sandra Månsson, with the first calScreener she built.
Our Production and Application Engineer, Sandra Månsson, with the first calScreener she built.
Why is antibiotic resistance a global threat? The challenges of antibiotic resistance, the current situation that marks it as a WHO priority and the potential of customized therapy are some of the issues that the CEO of Symcel, Dr Jesper Ericsson,...
Our colleague Dr. Karin Gillner recently had a feature article on brown fat treatment research published in Journal for Clinical Studies.
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
Internationally renowned clinical microbiologist takes academic lead in Horizon 2020 funded validation of game-changing method for multiple antibiotic resistance evaluation 11 April 2018: Symcel – the company behind the revolutionary cell-based...
L-R: Dr Marta Veses Garcia, Pelle Friberg and Dr Karin Gillner Symcel – producers of the cell-based assay tool for real-time cell metabolism measurements, calScreener — is expanding to bring its patented technology to the clinical antimicrobial...
Symcel secures €3.6 million Horizon 2020 Phase II grant for clinical validation of customized antimicrobial susceptibility testing. Multi-resistant bacterial sepsis infections to be validated utilising Symcel’s sensitive screening technology Symcel:...
Symcel AB today announces the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin who is now retiring. 1 September 2017: Symcel has today announced that Jesper Ericsson has joined Symcel as Chief Executive...